KYTX
Kyverna Therapeutics, Inc.
6.40$
+3.4%
vs. previous close
Closing price · As of: Oct 9, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +5.5% | +4.3% | +10.0% | +5.3% | +0.9% | -11.0% | +2.8% | -19.4% | -11.3% | -4.6% | +23.6% | – | |
| – | +50.5% | +190.6% | -43.6% | +165.8% | -59.5% | +56.4% | +16.5% | +7.2% | +0.1% | +17.4% | +10.6% | – | |
| – | -70.1% | -282.2% | – | +19.2% | -99.4% | -6,523.5% | – | -207.6% | – | -411.1% | – | – | |
| – | +30.5% | +62.6% | +89.3% | -90.1% | +421.6% | -100.0% | – | +92.2% | -98.7% | -100.0% | – | – | |
| – | – | -487.9% | -44.7% | – | +4,222.8% | -80.9% | +422.9% | -22.7% | -176.6% | +190.4% | – | – | |
| – | – | – | – | – | +2.1% | +38.1% | -23.2% | -54.2% | -29.2% | +1.2% | +10.5% | – | |
| – | -104.1% | – | -100.2% | -73.3% | +41.4% | +92.6% | +56.8% | – | +9,358.5% | -100.1% | – | – | |
| – | – | +1,523.1% | -148.9% | – | – | – | – | – | – | -202.2% | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 9, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.